Adnan K Chhatriwalla1, Keith B Allen2, John T Saxon2, David J Cohen2, Sanjeev Aggarwal2, Anthony J Hart2, Suzanne J Baron2, Danny Dvir2, A Michael Borkon2. 1. From the Saint Luke's Mid America Heart Institute, Kansas City, MO (A.K.C., K.B.A., J.T.S., D.J.C., S.A., A.J.H., S.J.B., A.M.B.); University of Missouri, Kansas City (A.K.C., K.B.A., J.T.S., D.J.C., S.A., A.J.H., S.J.B., A.M.B.); and St. Paul's Hospital, British Columbia, Canada (D.D.). achhatriwalla@saint-lukes.org. 2. From the Saint Luke's Mid America Heart Institute, Kansas City, MO (A.K.C., K.B.A., J.T.S., D.J.C., S.A., A.J.H., S.J.B., A.M.B.); University of Missouri, Kansas City (A.K.C., K.B.A., J.T.S., D.J.C., S.A., A.J.H., S.J.B., A.M.B.); and St. Paul's Hospital, British Columbia, Canada (D.D.).
Abstract
BACKGROUND: Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) may be less effective in small surgical valves because of patient/prosthesis mismatch. Bioprosthetic valve fracture (BVF) using a high-pressure balloon can be performed to facilitate VIV TAVR. METHODS AND RESULTS: We report data from 20 consecutive clinical cases in which BVF was successfully performed before or after VIV TAVR by inflation of a high-pressure balloon positioned across the valve ring during rapid ventricular pacing. Hemodynamic measurements and calculation of the valve effective orifice area were performed at baseline, immediately after VIV TAVR, and after BVF. BVF was successfully performed in 20 patients undergoing VIV TAVR with balloon-expandable (n=8) or self-expanding (n=12) transcatheter valves in Mitroflow, Carpentier-Edwards Perimount, Magna and Magna Ease, Biocor Epic and Biocor Epic Supra, and Mosaic surgical valves. Successful fracture was noted fluoroscopically when the waist of the balloon released and by a sudden drop in inflation pressure, often accompanied by an audible snap. BVF resulted in a reduction in the mean transvalvular gradient (from 20.5±7.4 to 6.7±3.7 mm Hg, P<0.001) and an increase in valve effective orifice area (from 1.0±0.4 to 1.8±0.6 cm2, P<0.001). No procedural complications were reported. CONCLUSIONS: BVF can be performed safely in small surgical valves to facilitate VIV TAVR with either balloon-expandable or self-expanding transcatheter valves and results in reduced residual transvalvular gradients and increased valve effective orifice area.
BACKGROUND: Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) may be less effective in small surgical valves because of patient/prosthesis mismatch. Bioprosthetic valve fracture (BVF) using a high-pressure balloon can be performed to facilitate VIV TAVR. METHODS AND RESULTS: We report data from 20 consecutive clinical cases in which BVF was successfully performed before or after VIV TAVR by inflation of a high-pressure balloon positioned across the valve ring during rapid ventricular pacing. Hemodynamic measurements and calculation of the valve effective orifice area were performed at baseline, immediately after VIV TAVR, and after BVF. BVF was successfully performed in 20 patients undergoing VIV TAVR with balloon-expandable (n=8) or self-expanding (n=12) transcatheter valves in Mitroflow, Carpentier-Edwards Perimount, Magna and Magna Ease, Biocor Epic and Biocor Epic Supra, and Mosaic surgical valves. Successful fracture was noted fluoroscopically when the waist of the balloon released and by a sudden drop in inflation pressure, often accompanied by an audible snap. BVF resulted in a reduction in the mean transvalvular gradient (from 20.5±7.4 to 6.7±3.7 mm Hg, P<0.001) and an increase in valve effective orifice area (from 1.0±0.4 to 1.8±0.6 cm2, P<0.001). No procedural complications were reported. CONCLUSIONS: BVF can be performed safely in small surgical valves to facilitate VIV TAVR with either balloon-expandable or self-expanding transcatheter valves and results in reduced residual transvalvular gradients and increased valve effective orifice area.
Authors: Jaffar M Khan; Danny Dvir; Adam B Greenbaum; Vasilis C Babaliaros; Toby Rogers; Gabriel Aldea; Mark Reisman; G Burkhard Mackensen; Marvin H K Eng; Gaetano Paone; Dee Dee Wang; Robert A Guyton; Chandan M Devireddy; William H Schenke; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2018-04-09 Impact factor: 11.195
Authors: Robert J Lederman; Vasilis C Babaliaros; Toby Rogers; Jaffar M Khan; Norihiko Kamioka; Danny Dvir; Adam B Greenbaum Journal: JACC Cardiovasc Interv Date: 2019-07-08 Impact factor: 11.195
Authors: Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Toby Rogers; Marvin H Eng; Gaetano Paone; Bradley G Leshnower; Mark Reisman; Lowell Satler; Ron Waksman; Marcus Y Chen; Annette M Stine; Xin Tian; Danny Dvir; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2019-06-12 Impact factor: 11.195
Authors: Sameer A Hirji; Edward D Percy; Cheryl K Zogg; Alexandra Malarczyk; Morgan T Harloff; Farhang Yazdchi; Tsuyoshi Kaneko Journal: Eur Heart J Date: 2020-08-01 Impact factor: 29.983
Authors: Dmitry Levin; G Burkhard Mackensen; Mark Reisman; James M McCabe; Danny Dvir; Beth Ripley Journal: Curr Cardiol Rep Date: 2020-02-17 Impact factor: 2.931